• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Artiva Biotherapeutics Inc.

    5/18/26 7:51:16 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARTV alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001621152
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ARTIVA BIOTHERAPEUTICS, INC.
    SEC File Number
    001-42179
    Address of Issuer
    5505 MOREHOUSE DRIVE, SUITE 100
    SAN DIEGO
    CALIFORNIA
    92121
    Phone
    (858) 267-4467
    Name of Person for Whose Account the Securities are To Be Sold
    Jennifer Bush
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Morgan Stanley Smith Barney LLC
    1 New York Plaza, 8th Floor
    New York � NY � 10004
    9000829804858819805/18/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock05/15/2026Restricted Stock Units vesting under registered planIssuerCheckbox not checked900005/15/2026Compensation for services rendered to Issuer

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    This is a sell-to-cover transaction for taxes owed related to recent vesting of stock unit awards granted by the Issuer.
    Date of Notice
    05/18/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jennifer Bush

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ARTV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARTV

    DatePrice TargetRatingAnalyst
    6/11/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$20.00Buy
    H.C. Wainwright
    8/13/2024$21.00Buy
    Jefferies
    8/13/2024$23.00Overweight
    Cantor Fitzgerald
    8/13/2024Buy
    TD Cowen
    8/13/2024$18.00Outperform
    Wedbush
    8/13/2024$23.00Buy
    Needham
    More analyst ratings

    $ARTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Committee of its Board of Directors approved new employee inducement grants covering an aggregate of 288,800 restricted stock units (the "Inducement Grants") for 17 new employees. The Inducement Grants were granted pursuant to Artiva’s 2025 Inducement Plan (the "Inducement Plan"), and were effective July 14, 2026. The Inducement Grants will vest over four years, with vesting aligned to quarterly vestin

    7/17/26 7:30:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

    SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026, at 3:30 pm EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available for replay on Artiva’s website for 90 days. About

    6/23/26 4:05:00 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

    Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosisLate-breaking oral presentation highlighted robust clinical responses with AlloNK plus rituximab across 31 patients with rheumatologic diseasesRheumatoid arthritis data showed clinically meaningful responses in highly refractory patients, including 71% ACR50 response at six months in the company-sponsored Phase 2a basket trialSafety and translational data support AlloNK's potential as an outpatient-administered, community-compatible deep B-cell depleting therapyU.S. Food and Drug Administratio

    6/8/26 6:30:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Artiva Biotherapeutics with a new price target

    H.C. Wainwright resumed coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $12.00

    6/11/25 7:52:47 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Artiva Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

    12/30/24 7:13:58 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies initiated coverage on Artiva Biotherapeutics with a new price target

    Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

    8/13/24 7:24:03 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $1,432,119 worth of shares (160,354 units at $8.93) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    7/20/26 6:08:52 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ra Capital Management, L.P. bought $194,040 worth of shares (21,654 units at $8.96) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    7/14/26 7:00:23 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ra Capital Management, L.P. bought $292,126 worth of shares (32,876 units at $8.89) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    6/29/26 4:20:33 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ARTV
    SEC Filings

    View All

    Director Ra Capital Management, L.P. bought $1,432,119 worth of shares (160,354 units at $8.93) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    7/20/26 6:08:52 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ra Capital Management, L.P. bought $194,040 worth of shares (21,654 units at $8.96) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    7/14/26 7:00:23 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ra Capital Management, L.P. bought $292,126 worth of shares (32,876 units at $8.89) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    6/29/26 4:20:33 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Artiva Biotherapeutics Inc.

    SCHEDULE 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    6/15/26 7:37:24 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Artiva Biotherapeutics Inc.

    8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

    5/19/26 8:07:26 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Artiva Biotherapeutics Inc.

    144 - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    5/18/26 7:53:05 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Leadership Updates

    Live Leadership Updates

    View All

    Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

    Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple therapeutics from discovery through FDA approval and commercialization, including PREZISTA® and INTELENCE® SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Dr. Miralles brings

    5/19/26 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

    SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation. "We are delighted to welcome Thad to Artiva as he brings strong late-stage development and comme

    2/24/26 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

    SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis. "We are thrilled to welcome Elaine to Artiva's board at such an imp

    2/19/26 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Artiva Biotherapeutics Inc.

    SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    11/14/24 4:56:18 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Artiva Biotherapeutics Inc.

    SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    9/3/24 4:18:05 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

    SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    8/1/24 7:00:07 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care